These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 24154871)

  • 21. Vismodegib.
    Meiss F; Andrlová H; Zeiser R
    Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
    Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
    Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GDC-0449-a potent inhibitor of the hedgehog pathway.
    Robarge KD; Brunton SA; Castanedo GM; Cui Y; Dina MS; Goldsmith R; Gould SE; Guichert O; Gunzner JL; Halladay J; Jia W; Khojasteh C; Koehler MF; Kotkow K; La H; Lalonde RL; Lau K; Lee L; Marshall D; Marsters JC; Murray LJ; Qian C; Rubin LL; Salphati L; Stanley MS; Stibbard JH; Sutherlin DP; Ubhayaker S; Wang S; Wong S; Xie M
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5576-81. PubMed ID: 19716296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.
    Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
    Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
    Frappaz D; Barritault M; Montané L; Laigle-Donadey F; Chinot O; Le Rhun E; Bonneville-Levard A; Hottinger AF; Meyronnet D; Bidaux AS; Garin G; Pérol D
    Neuro Oncol; 2021 Nov; 23(11):1949-1960. PubMed ID: 33825892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostaglandin E1 Inhibits
    Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y
    Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
    Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
    ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
    Dirix L; Rutten A
    Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
    Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ
    Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795
    [No Abstract]   [Full Text] [Related]  

  • 32. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
    Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM
    Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
    Meani RE; Lim SW; Chang AL; Kelly JW
    Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
    De Smaele E; Ferretti E; Gulino A
    Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma.
    Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ
    Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of Pin1 Suppresses Hedgehog-Driven Medulloblastoma Tumorigenesis.
    Xu T; Zhang H; Park SS; Venneti S; Kuick R; Ha K; Michael LE; Santi M; Uchida C; Uchida T; Srinivasan A; Olson JM; Dlugosz AA; Camelo-Piragua S; Rual JF
    Neoplasia; 2017 Mar; 19(3):216-225. PubMed ID: 28167297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vismodegib.
    Rudin CM
    Clin Cancer Res; 2012 Jun; 18(12):3218-22. PubMed ID: 22679179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis.
    Lou E; Nelson AC; Kool M
    Cancer Biol Ther; 2019; 20(11):1398-1402. PubMed ID: 31423907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.
    Abidi A
    Indian J Pharmacol; 2014; 46(1):3-12. PubMed ID: 24550577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.